Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.44 |
| ▸ | CTSL | P07711 | 6/20 | 0.42 |
| ▸ | CTSB | P07858 | 6/20 | 0.42 |
| ▸ | CTSH | P09668 | 4/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27505423 | 0.84 | REN (0.39) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL13889050 | 0.83 | CYP2D6 (0.44) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL27506204 | 0.82 | REN (0.37) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL14111950 | 0.82 | CTSK (0.41) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL27505427 | 0.80 | EPHX2 (0.46) | CTSKCTSLCTSBCTSHEPHX2 | |
| SCHEMBL13971410 | 0.79 | LTA4H (0.41) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL1716320 | 0.79 | LTA4H (0.44) | CTSKCTSLCTSBLTA4H | |
| SCHEMBL28808042 | 0.79 | LTA4H (0.41) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL27523284 | 0.79 | REN (0.34) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL27507024 | 0.78 | TSHR (0.44) | CTSKCTSLCTSBCTSHEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-9133199-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140066436-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | TETHRA BIOSCIENCES INC. | 2014-03-06 | — | — | US | disclosed |
| US-8563542-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2011-02-24 | — | — | US | disclosed |
| US-7615233-B2 | Particulate construct comprising polyhydroxyalkanoate and method for producing it | CANON KABUSHIKI KAISHA (JP) | 2009-11-10 | — | — | US | disclosed |
| US-7527809-B2 | Polyhydroxyalkanoate-containing magnetic structure, and manufacturing method and use thereof | CANON KABUSHIKI KAISHA (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7169598-B2 | Polyhydroxyalkanoate, method for production thereof and microorganisms for use in the same | CANON KABUSHIKI KAISHA (JP) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046093-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CDK7, CDK9, CDK8 | CTSK 3847/4885CTSL 4723/4885CTSB 4610/4885 |
| US-20140066436-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CDK7, CDK9, CDK8 | CTSK 3882/4885CTSL 4712/4885CTSB 4612/4885 |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | DCK, DTYMK, TK1 | CTSK 2661/4885CTSL 4348/4885CTSB 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.